Vaccination with inactivated or live-attenuated chimeric PCV1-2 results in decreased viremia in challenge-exposed pigs and may reduce transmission of PCV2

Veterinary Microbiology

Volumn 158, Issue 1-2, 2012, Pages 180-186

  Hemann, M ^a   Beach, N M ^b   Meng, X J ^b   Halbur, P G ^a   Opriessnig, T ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b CENTER FOR MOLECULAR MEDICINE AND INFECTIOUS DISEASES   (United States)

Author keywords

Porcine circovirus type 2; Transmission; Vaccination

Indexed keywords

FOSTERA; INACTIVATED VIRUS VACCINE; LIVE VACCINE; PORCINE CIRCOVIRUS TYPE 1 VACCINE; PORCINE CIRCOVIRUS TYPE 2 VACCINE; SUVAXYN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS DNA; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CIRCOVIRIDAE INFECTION; CONTROLLED STUDY; EXPERIMENTAL PIG; INFECTION PREVENTION; LYMPHOID TISSUE; NONHUMAN; PORCINE CIRCOVIRUS TYPE 2 INFECTION; VACCINATION; VIREMIA; VIRUS TRANSMISSION;

ANIMALS; ANTIBODIES, NEUTRALIZING; CIRCOVIRIDAE INFECTIONS; CIRCOVIRUS; LYMPHOID TISSUE; SPECIFIC PATHOGEN-FREE ORGANISMS; SUS SCROFA; SWINE; SWINE DISEASES; VACCINES, ATTENUATED; VACCINES, INACTIVATED; VIRAL VACCINES;

ANIMALIA; PORCINE CIRCOVIRUS 2; SUIDAE;

EID: 84861580031     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2012.01.024     Document Type: Article

References (23)

1. Beach N.M., Ramamoorthy S., Opriessnig T., Wu S.Q., Meng X.J. Novel chimeric porcine circovirus (PCV) with the capsid gene of the emerging PCV2b subtype cloned in the genomic backbone of the non-pathogenic PCV1 is attenuated in vivo and induces protective and cross-protective immunity against PCV2b and PCV2a subtypes in pigs. Vaccine 2010, 29:221-232.
2. Bolin S.R., Stoffregen W.C., Nayar G.P., Hamel A.L. Postweaning multisystemic wasting syndrome induced after experimental inoculation of cesarean-derived, colostrum-deprived piglets with type 2 porcine circovirus. J. Vet. Diagn. Invest. 2001, 13:185-194.
3. Fenaux M., Opriessnig T., Halbur P.G., Elvinger F., Meng X.J. A chimeric porcine circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2 (PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces protective immunity against PCV2 infection in pigs. J. Virol. 2004, 78:6297-6303.
4. Fenaux M., Opriessnig T., Halbur P.G., Meng X.J. Immunogenicity and pathogenicity of chimeric infectious DNA clones of pathogenic porcine circovirus type 2 (PCV2) and nonpathogenic PCV1 in weanling pigs. J. Virol. 2003, 77:11232-11243.
5. Fort M., Sibila M., Perez-Martin E., Nofrarias M., Mateu E., Segales J. One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model. Vaccine 2009, 27:4031-4037.
6. Gillespie J., Opriessnig T., Meng X.J., Pelzer K., Buechner-Maxwell V. Porcine circovirus type 2 and porcine circovirus-associated disease. J. Vet. Intern. Med. 2009, 23:1151-1163.
7. Halbur P.G., Paul P.S., Frey M.L., Landgraf J., Eernisse K., Meng X.J., Lum M.A., Andrews J.J., Rathje J.A. Comparison of the pathogenicity of two US porcine reproductive and respiratory syndrome virus isolates with that of the Lelystad virus. Vet. Pathol. 1995, 32:648-660.
8. Martín H., Le Potier M.F., Maris P. Virucidal efficacy of nine commercial disinfectants against porcine circovirus type 2. Vet. J. 2008, 177:388-393.
9. Nawagitgul P., Harms P.A., Morozov I., Thacker B.J., Sorden S.D., Lekcharoensuk C., Paul P.S. Modified indirect porcine circovirus (PCV) type 2-based and recombinant capsid protein (ORF2)-based enzyme-linked immunosorbent assays for detection of antibodies to PCV. Clin. Diagn. Lab. Immunol. 2002, 9:33-40.
10. Opriessnig T., Meng X.J., Halbur P.G. Porcine circovirus type 2 associated disease: update on current terminology, clinical manifestations, pathogenesis, diagnosis, and intervention strategies. J. Vet. Diagn. Invest. 2007, 19:591-615.
11. Opriessnig T., Patterson A.R., Madson D.M., Pal N., Ramamoorthy S., Meng X.J., Halbur P.G. Comparison of the effectiveness of passive (dam) versus active (piglet) immunization against porcine circovirus type 2 (PCV2) and impact of passively derived PCV2 vaccine-induced immunity on vaccination. Vet. Microbiol. 2010, 142:177-183.
12. Opriessnig T., Ramamoorthy S., Madson D.M., Patterson A.R., Pal N., Carman S., Meng X.J., Halbur P.G. Differences in virulence among porcine circovirus type 2 isolates are unrelated to cluster type 2a or 2b and prior infection provides heterologous protection. J. Gen. Virol. 2008, 89:2482-2491.
13. Opriessnig T., Shen H.G., Pal N., Ramamoorthy S., Halbur P.G. A live-attenuated chimeric PCV2 vaccine is transmitted to contact pigs but is not upregulated by concurrent infection with PPV and PRRSV and is efficacious in a PCV2a-PRRSV-PPV challenge model. Clin. Vaccine Immunol. 2011, 18:1261-1268.
14. Opriessnig T., Thacker E.L., Yu S., Fenaux M., Meng X.J., Halbur P.G. Experimental reproduction of postweaning multisystemic wasting syndrome in pigs by dual infection with Mycoplasma hyopneumoniae and porcine circovirus type 2. Vet. Pathol. 2004, 41:624-640.
15. Opriessnig T., Yu S., Gallup J.M., Evans R.B., Fenaux M., Pallarés F.J., Thacker E.L., Brockus C.W., Ackermann M.R., Thomas P., Meng X.J., Halbur P.G. Effect of vaccination with selective bacterins on conventional pigs infected with type 2 porcine circovirus. Vet. Pathol. 2003, 40:521-529.
16. Opriessnig T., Prickett J.R., Madson D.M., Shen H.G., Juhan N.M., Pogranichniy R.R., Meng X.-J., Halbur P.G. Porcine circovirus type 2 (PCV2)-infection and re-inoculation with homologous or heterologous strains: virological, serological, pathological and clinical effects in growing pigs. Vet. Res. 2010, 41:31.
17. Patterson A.R., Baker R.B., Madson D.M., Pintar A.L., Opriessnig T. Disinfection protocols reduce the amount of porcine circovirus type 2 in contaminated 1:61 scale model livestock transport vehicles. J. Swine Health Prod. 2011, 19:156-164.
18. Patterson A.R., Opriessnig T. Epidemiology and horizontal transmission of porcine circovirus type 2 (PCV2). Anim. Health Res. Rev. 2010, 11:217-234.
19. Patterson A.R., Ramamoorthy S., Madson D.M., Meng X.J., Halbur P.G., Opriessnig T. Shedding and infection dynamics of porcine circovirus type 2 (PCV2) after experimental infection. Vet. Microbiol. 2011, 149:91-98.
20. Pogranichniy R.M., Yoon K.J., Harms P.A., Swenson S.L., Zimmerman J.J., Sorden S.D. Characterization of immune response of young pigs to porcine circovirus type 2 infection. Viral Immunol. 2000, 13:143-153.
21. Shen H.G., Beach N., Huang Y.W., Halbur P.G., Meng X.J., Opriessnig T. Comparison of commercial and experimental porcine circovirus type 2 (PCV2) vaccines using a triple challenge with PCV2, porcine reproductive and respiratory syndrome virus (PRRSV), and porcine parvovirus (PPV). Vaccine 2010, 28:5960-5966.
22. Sorden S.D., Harms P.A., Nawagitgul P., Cavanaugh D., Paul P.S. Development of a polyclonal-antibody-based immunohistochemical method for the detection of type 2 porcine circovirus in formalin-fixed, paraffin-embedded tissue. J. Vet. Diagn. Invest. 1999, 11:528-530.
23. Xujie L., Xiaobo W., Yi S., Jing F., Song G., Xiufan L. A candidate inactivated chimeric vaccine PCV1-2 constructed based on PCV1 and PCV2 isolates originating in China and its evaluation in conventional pigs in regard to protective efficacy against PCV2 infection. Microbiol. Immunol. 2011, 55:254-266.